and 15.16 μM, respectively than the positive drug kojicacid (IC50 with 30.83 μM). The cytotoxicity evaluation showed that compounds 13 and 14 have higher safety than the other compounds to the proliferation of B16F10 cells. The result of the melanocyte test supported that compound13 has stronger cellular tyrosinase inhibitory activity than kojicacid and arbutin at 100 μM and 200 μM. The enzyme kinetics